In June 2020, the U.S. Food Drug and Administration approved Keytruda (Merck) with fluorouracil, leucovorin and oxaliplatin as a first line drug treatment for colorectal cancer.
In 2016, the University of Health, Toronto, completed its clinical trial of Abraxane and Cisplatin and 5–fluorouracil as inductory chemotherapy treatment in head and neck cancer.